See more : Aves One AG (AVES.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Trident Lifeline Limited (TLL.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trident Lifeline Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- AutoNation, Inc. (AN) Income Statement Analysis – Financial Results
- Sempra (SRE) Income Statement Analysis – Financial Results
- Nexus Infrastructure plc (NEXS.L) Income Statement Analysis – Financial Results
- Indo Cotspin Limited (ICL.BO) Income Statement Analysis – Financial Results
- Embracer Group AB (publ) (THQQF) Income Statement Analysis – Financial Results
Trident Lifeline Limited (TLL.BO)
About Trident Lifeline Limited
Trident Lifeline Ltd. manufactures and markets pharmaceutical products. It is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. The firm offers pharmaceutical formulations and products manufactured on contract manufacturing under loan licence. The company was founded on January 9, 2014 and is headquartered in Surat, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 446.29M | 316.92M | 217.68M | 96.22M | 49.35M |
| Cost of Revenue | 327.20M | 243.36M | 181.67M | 76.30M | 44.94M |
| Gross Profit | 119.08M | 73.56M | 36.01M | 19.92M | 4.41M |
| Gross Profit Ratio | 26.68% | 23.21% | 16.54% | 20.70% | 8.93% |
| Research & Development | 37.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.87M | 18.54M | 10.18M | 8.85M | 8.26M |
| Other Expenses | -37.00K | 6.84M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.87M | 11.70M | 10.18M | 8.85M | 8.26M |
| Cost & Expenses | 374.08M | 255.06M | 191.85M | 85.15M | 53.20M |
| Interest Income | 0.00 | 4.47M | 0.00 | 14.00K | 0.00 |
| Interest Expense | 6.04M | 4.66M | 1.26M | 4.12M | 7.62M |
| Depreciation & Amortization | 9.70M | 3.65M | 2.03M | 1.44M | 1.15M |
| EBITDA | 102.69M | 65.50M | 33.12M | 14.10M | -2.70M |
| EBITDA Ratio | 23.01% | 20.67% | 12.79% | 13.00% | -5.47% |
| Operating Income | 72.21M | 61.86M | 25.83M | 11.07M | -3.85M |
| Operating Income Ratio | 16.18% | 19.52% | 11.86% | 11.51% | -7.81% |
| Total Other Income/Expenses | 14.74M | 3.97M | 4.01M | -2.53M | -6.90M |
| Income Before Tax | 86.95M | 65.83M | 29.84M | 8.54M | -10.75M |
| Income Before Tax Ratio | 19.48% | 20.77% | 13.71% | 8.87% | -21.79% |
| Income Tax Expense | 27.56M | 5.64M | -9.64M | 2.22M | -2.79M |
| Net Income | 63.44M | 60.15M | 39.48M | 6.32M | -7.96M |
| Net Income Ratio | 14.21% | 18.98% | 18.14% | 6.57% | -16.14% |
| EPS | 5.52 | 6.23 | 6.92 | 0.79 | -1.00 |
| EPS Diluted | 5.52 | 6.23 | 6.92 | 0.79 | -1.00 |
| Weighted Avg Shares Out | 11.50M | 9.66M | 5.71M | 8.00M | 8.00M |
| Weighted Avg Shares Out (Dil) | 11.50M | 9.66M | 5.71M | 8.00M | 8.00M |
Source: https://incomestatements.info
Category: Stock Reports